Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency.
Matthews RP, Cao Y, Patel M, Weissler VL, Bhattacharyya A, De Lepeleire I, Last S, Rondon JC, Vargo R, Stoch SA, Iwamoto M. Matthews RP, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093122. doi: 10.1128/aac.00931-22. Epub 2022 Nov 8. Antimicrob Agents Chemother. 2022. PMID: 36346229 Free PMC article. Clinical Trial.
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M. Anderson MS, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32. doi: 10.1128/AAC.00487-08. Epub 2008 Oct 6. Antimicrob Agents Chemother. 2008. PMID: 18838586 Free PMC article. Clinical Trial.
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Breidinger SA, Mangin EC, Azrolan N, Greenberg HE, Haazen W, Stone JA, Gottesdiener KM, Wagner JA. Iwamoto M, et al. Antimicrob Agents Chemother. 2008 Dec;52(12):4338-43. doi: 10.1128/AAC.01543-07. Epub 2008 Oct 6. Antimicrob Agents Chemother. 2008. PMID: 18838589 Free PMC article. Clinical Trial.
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Iwamoto M, Hanley WD, Petry AS, Friedman EJ, Kost JT, Breidinger SA, Lasseter KC, Robson R, Lunde NM, Wenning LA, Stone JA, Wagner JA. Iwamoto M, et al. Antimicrob Agents Chemother. 2009 May;53(5):1747-52. doi: 10.1128/AAC.01194-08. Epub 2009 Feb 17. Antimicrob Agents Chemother. 2009. PMID: 19223645 Free PMC article. Clinical Trial.
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M. Wenning LA, et al. Among authors: iwamoto m. Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11. Clin Pharmacol Ther. 2009. PMID: 19279563 Clinical Trial.
Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
Hanley WD, Wenning LA, Moreau A, Kost JT, Mangin E, Shamp T, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M. Hanley WD, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2009 Jul;53(7):2752-5. doi: 10.1128/AAC.01486-08. Epub 2009 Apr 27. Antimicrob Agents Chemother. 2009. PMID: 19398643 Free PMC article. Clinical Trial.
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, Marbury TC, Berg JK, Chodakewitz JA, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M. Wenning LA, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6. doi: 10.1128/AAC.01468-08. Epub 2009 May 11. Antimicrob Agents Chemother. 2009. PMID: 19433563 Free PMC article. Clinical Trial.
Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.
Khalilieh S, Yee KL, Sanchez RI, Triantafyllou I, Fan L, Maklad N, Jordan H, Martell M, Iwamoto M. Khalilieh S, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01364-16. doi: 10.1128/AAC.01364-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27872071 Free PMC article. Clinical Trial.
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW. Caro L, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec. Antimicrob Agents Chemother. 2017. PMID: 28947470 Free PMC article. Clinical Trial.
1,451 results